Why Pharma Investors Should Watch the Dual-Pathway Biotech Model

The pharmaceutical investing playbook has a structural problem. According to the National Institute of Health, 80-90% of research projects fail before reaching human trials, and 95% of compounds that do enter clinical testing fail in development. The average new drug takes more than 13 years to progress from initial discovery to FDA approval, with most clinical-stage companies generating no revenue during that period and funding themselves through repeated rounds of dilutive financing.

For investors, the model produces a particular set of incentives. Bet big on a small number of candidates, expect most to fail, and rely on the rare success to compensate for the rest. It works at the portfolio level for large pharmaceutical funds. It works less well for individual investors trying to identify specific companies likely to survive the gauntlet.

A handful of clinical-stage developers are starting to build an alternative model, and it deserves attention from pharma and medtech investors looking to participate in the cancer drug pipeline without taking on single-asset, all-or-nothing risk.

The Dual-Pathway Approach

Others are doing it differently. The concept is straightforward. A company develops a pharmaceutical asset, typically a clinical-stage drug, while simultaneously operating a related commercial business in an adjacent regulatory category. The drug program runs on traditional pharma timelines, with milestones tied to FDA trials. The commercial business generates revenue from day one, often funding part of the company’s operations and creating direct customer relationships that inform later development.

When the underlying science genuinely supports both products, the model produces several investor-relevant benefits. The clinical-stage company has a non-zero floor under its valuation. Operating cash flow reduces dependence on dilutive financing rounds. Customer feedback from the commercial business surfaces signals that the drug program can act on. The company has more flexibility in tight capital markets than competitors that rely solely on milestone-driven financing.

The model is not appropriate for every clinical-stage developer. It works only when the underlying science can credibly support two distinct products in two regulatory categories. Most synthetic chemistry programs cannot. Botanical and natural-product programs often can.

NextGen Scientific as a Working Example

NextGen Scientific, headquartered in Sterling, Kansas, runs exactly this model. The company’s pharmaceutical program centers on GZ17-6.02, an oral cancer drug derived from the plant Arum palaestinum. The drug completed its Phase 1 trial in patients with advanced solid tumors and lymphoma, with results published in Annals of Oncology in 2021. 

There is an active Phase 1b trial sponsored by Virginia Commonwealth University to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer. It is a single-arm study in men previously treated with androgen deprivation therapy and an androgen receptor pathway inhibitor, and all participants receive the drug. 

In parallel, NextGen owns Hyatt Life Sciences, a premium dietary supplement brand sold through Walmart.com and the company’s own e-commerce platform. The supplement line is built on a proprietary blend, branded Afaya, of the same Arum palaestinum plant combined with Peganum harmala and turmeric. The supplement business is currently generating revenue, supported by two granted U.S. patents and FDA New Dietary Ingredient notifications for both Arum palaestinum and Peganum harmala. According to the company, it is the only entity in the United States with both notifications cleared.

The business structure runs both programs under one corporate umbrella while maintaining strict regulatory separation. The drug program is regulated under the Federal Food, Drug, and Cosmetic Act, with marketing claims tied to eventual Phase 2 and Phase 3 efficacy data. The supplement line operates under the Dietary Supplement Health and Education Act of 1994, where specific medical claims are not permitted.

What gives the structure operational credibility is the protection built around the source plant. Six greenhouses in Kansas provide a controlled domestic supply. The FDA NDI notifications create a regulatory moat. The patents create an intellectual property moat. And the same active compounds inform both the drug and the supplement, meaning research investment in one program builds knowledge applicable to the other.

What the Model Looks Like From an Investor Perspective

For investors evaluating clinical-stage opportunities, the dual-pathway structure changes the analysis in three concrete ways.

First, the all-or-nothing risk profile flattens. A purely clinical-stage company is worth a great deal if the drug works and roughly nothing if it does not. A dual-pathway company with a meaningful commercial business has a floor tied to the supplement valuation, even if the drug program is delayed or terminated.

Second, the capital requirements over time are lower. NextGen and affiliates have raised approximately $75 million to date, supporting both pathways. A pure-play clinical-stage developer running similar trials without parallel revenue would likely have required more capital, and would still face the same dilution pressure in future rounds.

Third, the exit menu expands. A clinical-stage drug developer typically has one realistic exit: licensing or acquisition by a larger pharmaceutical company once the drug has been derisked through Phase 2 or Phase 3. A dual-pathway company has at least three potential exits: the same drug-licensing transaction, an acquisition of the supplement business by a consumer-health acquirer, or continued independent operation, with the supplement business funding ongoing drug development.

A Category Worth Watching

The traditional pharma playbook produces results, but at the cost of brutal failure rates, multi-decade timelines, and the all-or-nothing risk that has frustrated retail and institutional investors alike. The dual-pathway approach offers a different way to build long-term value while creating short-term resilience.

For investors interested in the cancer drug pipeline who want some protection against the standard biotech failure curve, companies like NextGen Scientific represent a category worth understanding.